Clinical Trial Update: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase [Phase 3]

View source ↗

Summary

Phase 3 study assessing 6-month efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes, including extension phase.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome
• Neonatal-onset Multisystem Inflammatory Disease

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome | Phase 3 | Status: COMPLETED